

## PRESS CLIPPING SHEET

<b>PUBLICATION:</b>	Daily News
<b>DATE:</b>	11-March-2019
<b>COUNTRY:</b>	Egypt
<b>CIRCULATION:</b>	80,000
<b>TITLE :</b>	Novartis Launches first Summit to Probe Cancer, haematological oncology treatment in Egypt
<b>PAGE:</b>	06
<b>ARTICLE TYPE:</b>	Agency-Generated News
<b>REPORTER:</b>	Staff Report
<b>AVE:</b>	19,530

### Novartis launches first summit to probe cancer, haematological oncology treatment in Egypt

Novartis Pharma held the first conference focused on haematological oncology and blood disease treatments in Egypt, titled "Reimagining Cancer". The conference is part of the company's ongoing commitment toward cancer patients and their access to the best and most advanced medication available.

Fourteen universities and institutes and more than 350 guests, as well as 70 local and two international speakers were invited to in-depth discussions on cancer and haematological disorders, including thalassemia, chronic leukaemia, breast cancer, and neuroendocrine tumours and their treatments.

"The conference showcased Novartis Pharma's vision, support for patients, and healthcare providers as well as highlighted the significant scientific research and development efforts required to diversify treatment options for patients," Sherif Amin, Novartis Oncology general manager for Egypt, Libya, Tunisia, and Morocco said.

The conference also addressed specific haematological disorders prevalent in Egypt, such as thalassemia, a severe form of anaemia that is most often of a hereditary origin, of which 9% of Egyptians are carriers of the gene that is at the root of the disease—which is one of the highest rates in the world.

